{"id":"zolpidem-sl800750","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Drowsiness/somnolence"},{"rate":"5-10%","effect":"Headache"},{"rate":"1-5%","effect":"Amnesia/memory impairment"},{"rate":"<1%","effect":"Complex sleep behaviors"},{"rate":"variable with duration of use","effect":"Dependence/tolerance"}]},"_chembl":{"chemblId":"CHEMBL3989820","moleculeType":"Small molecule","molecularWeight":"764.88"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Zolpidem acts as a positive allosteric modulator of GABA-A receptors, enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) and increasing chloride ion influx into neurons. This hyperpolarizes neuronal membranes and reduces neuronal excitability, leading to sedation and sleep induction. It has selective affinity for the alpha-1 subunit of GABA-A receptors, which contributes to its hypnotic properties with relatively less muscle relaxation or anticonvulsant activity compared to non-selective benzodiazepines.","oneSentence":"Zolpidem is a sedative-hypnotic that selectively binds to benzodiazepine receptors on GABA-A channels in the central nervous system to promote sleep onset.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:16:47.016Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Insomnia (sleep onset and maintenance)"},{"name":"Short-term treatment of insomnia in adults"}]},"trialDetails":[{"nctId":"NCT01024192","phase":"PHASE4","title":"Efficacy and Safety Assessment of ZOlpidem (Stilnox CR) in Patients With Chronic insomNIA","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-11","conditions":"Sleep Disorders","enrollment":135},{"nctId":"NCT00630175","phase":"PHASE3","title":"Evaluation of the Hypnotic Properties of Zolpidem-MR 12.5 mg and Zolpidem 10 mg Marketed Product Compared to Placebo in Patients With Primary Insomnia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-09","conditions":"Sleep Initiation and Maintenance Disorders","enrollment":113},{"nctId":"NCT00318448","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of Ambien (Zolpidem) in the Treatment of Children Ages 6 to 17 With Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-04","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":201},{"nctId":"NCT00425243","phase":"PHASE3","title":"Efficacy and Safety of Zolpidem-MR Administered Over a Long Term Period as Needed for Insomnia (ZOLONG)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-08","conditions":"Sleep Initiation and Maintenance Disorders","enrollment":1025}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Zolpidem (SL800750)","genericName":"Zolpidem (SL800750)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Zolpidem is a sedative-hypnotic that selectively binds to benzodiazepine receptors on GABA-A channels in the central nervous system to promote sleep onset. Used for Insomnia (sleep onset and maintenance), Short-term treatment of insomnia in adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}